Global CNS Therapeutics Market 2018-2022 - Key Vendors are Eli Lilly, F. Hoffmann-La Roche, Johnson & Johnson, Merck & Novartis - ResearchAndMarkets.com

June 13, 2018

DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Global CNS Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global CNS therapeutics market to grow at a CAGR of 4.36% during the period 2018-2022.

Global CNS Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. CNS therapeutics cater to CNS disorders that affect the structure or function of the brain or spinal cord such as Parkinson’s disease, epilepsy, Alzheimer’s disease, anxiety, depression, and bipolar disorders. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of therapeutics for CNS disorders.

The increased adoption of new-generation drugs will be a key trend for the market growth. First-generation and second-generation drugs have many side-effects, limited therapeutic range, and complicated pharmacokinetics. Third-generation drugs have longer therapeutic ranges and limited side effects in comparison to the second-generation drugs, driving the adoption of third-generation drugs.

According to the report, the increasing prevalence of mental illness will drive the market growth. Mental disorders coexist with diseases such as diabetes, cardiovascular disease, or obesity. The increased disease burden and mental disorders requires the availability of effective therapeutics for mental health to decrease the number of deaths caused due to mental illness.

Further, the report states that the side effects of CNS therapeutics will impact the market growth. Therapeutics for CNS disorders have numerous risks and side-effects such as drowsiness and weight gain, insomnia, lowered libido, tremors, and agitation. Also, anti-epilepsy medications result in periodic mood swings that are consequent in depression and anxiety.

Market Trends

Increasing awareness programs Increased adoption of new-generation drugs Advances in technology in treating mental disorders

Key vendors

Eli Lilly F. Hoffmann-La Roche Johnson & Johnson Merck Novartis

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Market Sizing

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Market Segmentation By End-User

Part 09: Regional Landscape

Part 10: Decision Framework

Part 11: Drivers And Challenges

Part 12: Market Trends

Part 13: Vendor Landscape

Part 14: Vendor Analysis

Part 15: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/32hh8p/global_cns?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006065/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/13/2018 02:06 PM/DISC: 06/13/2018 02:07 PM


Update hourly